证券代码：300138 证券简称：晨光生物 公告编号：2024—146 晨光生物科技集团股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（以下简称"公司"）于 2023 年 9 月 21 日召开的第五届董事会第三次会议、第五届监事会第三次会议审议通过了《关于 使用部分闲置募集资金进行现金管理的议案》。同意公司在不影响募集资金投资 项目建设的前提下，使用不超过 2 亿元暂时闲置募集资金进行现金管理，用于购 买安全性高、流动性好的理财产品/结构性存款产品等，期限为自董事会审议通 过之日起不超过 12 个月，期限内在上述资金额度范围内滚动使用（详细内容请 见 2023 年 9 月 22 日披露于巨潮资讯网的相关公告文件）。 前期，公司使用暂时闲置募集资金 3,000 万元购买了德邦证券股份有限公司 收益凭证（详细内容请见 2023 年 11 月 14 日披露于巨潮资讯网的《关于使用部 分闲置募集资金进行现金管理的进展公告》）。截至 2024 年 11 月 15 日，上述 理财产 ...

证券代码：300138 证券简称：晨光生物 公告编号：2024—147 统一社会信用代码：91530522MA6N2BT715 晨光生物科技集团股份有限公司 关于子公司完成变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司因业务发展需要，决定变更子公司——晨光 生物科技集团腾冲有限公司（简称"腾冲晨光"）经营范围及住所，相关的变更 登记事项已于近日办理完成，并取得了腾冲市市场监督管理局核发的营业执照， 登记的相关信息如下： 名 称：晨光生物科技集团腾冲有限公司 类 型：有限责任公司 法定代表人 ：王璞 备修理；农林牧副渔业专业机械的安装、维修；复合微生物肥料研发；农林牧副 渔业专业机械的制造；技术服务、技术开发、技术咨询、技术交流、技术转让、 技术推广；食用农产品批发；食用农产品零售；初级农产品收购；饲料原料销售； 饲料添加剂销售；饲料生产专用设备销售。 腾冲晨光本次变更登记主要是经营范围增加："饲料生产；饲料添加剂生产； 饲料原料销售；饲料添加剂销售；饲料生产专用设备销售"，住所变更为：云南 省保山市腾冲市中和镇经济 ...

关于子公司归还银行借款暨为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（以下简称"公司"）及子公司新疆晨光生 物科技股份有限公司（以下简称"新疆晨光"）对合并报表范围内子公司银行借 款担保情况因业务进展发生了变动，现公告如下： 一、对外担保基本情况及进展 1、结合自身经营流动资金需求，经公司 2022 年年度股东大会决议，喀什晨 光植物蛋白有限公司（以下简称"喀什蛋白"，系新疆晨光全资子公司，穿透后 为公司控股子公司）前期向乌鲁木齐银行股份有限公司喀什分行（以下简称"乌 鲁木齐银行喀什分行"）申请办理了 8,000 万元流动资金借款。担保方式为：公 司保证担保。 公司与乌鲁木齐银行喀什分行签署了《保证合同》，担保金额：8,000 万元； 保证方式为：连带责任保证；保证期间为：自《保证合同》生效之日起至主合同 约定的债务履行期限届满之日起三年；保证范围：主债务本金及利息、逾期利息、 违约利息、复利、违约金、赔偿金以及为实现债权而产生的一切费用（详见 2023 年11月6日披露于巨潮资讯网的《关于为子公司银 ...

证券代码：300138 证券简称：晨光生物 公告编号：2024—144 晨光生物科技集团股份有限公司 关于为子公司银行借款提供担保的进展公告 经过核查，昆仑银行同意了图木舒克晨光及喀什蛋白的借款申请，借款金额分别 为：4,000 万元、3,000 万元，担保方式为：公司保证担保。 公司与昆仑银行分别就上述借款事宜签署了《保证合同》，担保的主债权为 昆仑银行依据其与图木舒克晨光及喀什蛋白签订的主合同而享有的对债务人的 债权，金额分别为：4,000 万元、3,000 万元；保证方式为：连带责任保证；保 证期间为：自主合同项下的每笔债务借款期限届满之次日起三年；保证范围为： 主债权本金、利息、复利（含期内利息、逾期未付利息）、罚息、违约金、损害 赔偿金、汇率损失（因汇率变动引起的相关损失）以及实现债权的费用（包括但 不限于诉讼费、仲裁费、律师费、保全费、鉴定费、执行费、拍卖费等）。 2、因原料集中采购，结合自身经营流动资金需求，喀什蛋白近日向中国农 业银行股份有限公司岳普湖县支行（以下简称"岳普湖县农行"）提出流动资金 借款申请。经过核查，岳普湖县农行同意了喀什蛋白的借款申请，借款金额为 9,000 万元，担保方式 ...

证券代码：300138 证券简称：晨光生物 公告编号：2024—142 二、韩国专利管理部门专利授权情况 | 专利名称 | 申请号 | 专利号 | | | 授权日期 | | | | 有效期 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 一种具有保鲜功能的番 | | | | | | | | | | | | 茄红素着色剂及其制备 | 10-2023-7014649 | 10-2706206 | 2024 | 年 | 09 | 月 | 09 | 日 | 20 | 年 | | 方法与应用 | | | | | | | | | | | "一种具有保鲜功能的番茄红素着色剂及其制备方法与应用"涉及食品工业 领域，本发明所得番茄红素着色剂粒度适中，色调适合鱼糜类产品的涂色，着色 力强，色彩鲜艳，具有促发肌红蛋白的效果，使鱼糜类产品色泽鲜艳，具有保鲜 功能，可杀灭部分食品微生物，从而使食品保鲜，增加了货架期。 晨光生物科技集团股份有限公司 关于公司及子公司取得专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 ...

证券代码：300138 证券简称：晨光生物 公告编号：2024—143 晨光生物科技集团股份有限公司（简称"公司"）第五届董事会第九次会议、 2023 年年度股东大会审议通过了《关于公司与子公司或子公司之间融资担保的 议案》，同意公司及合并报表范围内各级子公司在 2023 年年度股东大会审议通 过之日起至 2024 年年度股东大会召开日，向融资机构申请办理各类融资业务余 额不超 60 亿元；融资担保方式涉及公司合并报表范围内各主体之间担保：公司 向合并报表范围内各级子公司或各级子公司之间融资担保余额不超过 32 亿元， 其中：向子公司新疆晨光生物科技股份有限公司（简称"新疆晨光"）及其合并 报表范围内子公司提供担保的余额不超过 25 亿元（含新疆晨光合并报表范围内 各主体互相担保），向其他子公司提供担保或其他子公司之间互相担保的余额不 超过7亿元。公司股东大会授权董事会在融资担保余额不超过32亿元的前提下， 结合合并报表范围内各子公司资产负债率、融资授信及放款等情况，具体调整被 担保的子公司及对其担保额度(相关文件已于 2024 年 4 月 18 日、2024 年 5 月 9 日公告于巨潮资讯网)。 二、对外 ...

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the context suggests a neutral to cautious outlook based on recent performance and future expectations [19]. Core Insights - The company reported a revenue of 5.23 billion yuan for the first three quarters of 2024, reflecting a year-on-year increase of 1.1%, while the net profit attributable to shareholders was 63 million yuan, down 84.3% year-on-year [2]. - The revenue for Q3 2024 was 1.73 billion yuan, showing a year-on-year increase of 15.6%, but the net profit was negative at -37 million yuan, a decline of 137.3% year-on-year, primarily due to losses in cottonseed and asset impairment [2]. - The plant extraction business showed steady growth with a revenue of 2.33 billion yuan in the first three quarters, up 11.1% year-on-year, while the cottonseed business revenue was 2.63 billion yuan, down 5.8% year-on-year [3][4]. Summary by Sections Financial Performance - For the first three quarters of 2024, the gross margin decreased by 4.9 percentage points to 7.4%, with Q3 gross margin down 7.8 percentage points to 5.5% due to increased raw material supply and weak downstream demand [5]. - The company expects net profits for 2024 to be 150 million yuan, with EPS projected at 0.31 yuan, and a gradual recovery in profits anticipated in 2025 and 2026 [6][8]. Business Segments - The plant extraction segment is performing well, with key products like chili red and lutein showing stable sales and growth, while the cottonseed segment is under pressure due to increased competition and fluctuating commodity prices [3][4]. - The company is actively developing its health food segment, achieving over 120 million yuan in revenue, a year-on-year increase of 11.5% [3]. Market Position and Strategy - The company is recognized as a leader in the plant extraction industry, with a focus on diversifying its product offerings and enhancing market share in high-margin products [13]. - The long-term trend of increasing market share remains strong, with expectations for improved profitability as the company continues to adjust its operational strategies [7].

晨光生物科技集团股份有限公司 关于计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（简称"公司"）根据《企业会计准则》等 有关规定，经第五届董事会第十三次会议、第五届监事会第十二次会议审议通过 《关于计提资产减值准备的议案》，同意对公司前三季度可能发生资产减值损失 的相关资产计提资产减值准备。现根据《深圳证券交易所上市公司自律监管指引 第 2 号——创业板上市公司规范运作》《深圳证券交易所创业板上市公司自律监 管指南第 1 号——业务办理》等相关规定，将具体内容公告如下： 证券代码：300138 证券简称：晨光生物 公告编号：2024—141 一、本次计提资产减值准备情况概述 1、本次计提资产减值准备的原因 根据《企业会计准则》及公司会计政策的相关规定，为了更加真实、准确地 反映公司的经营情况，公司对合并报表范围内各类资产进行了全面清查、分析和 评估，认为上述资产中存货存在一定的减值迹象，基于谨慎性原则，对截至 2024 年 9 月 30 日可能发生资产减值损失的相关资产计提减值准备。 2、本次计提资产减值准 ...

Revenue and Profit - Revenue for Q3 2024 reached ¥1,734,499,040.21, an increase of 15.58% compared to the same period last year[2] - Net profit attributable to shareholders was -¥37,228,735.86, a decrease of 137.34% year-on-year[2] - Net profit excluding non-recurring items was -¥65,485,036.37, down 172.68% from the previous year[2] - The net profit for Q3 2024 was CNY 45,240,156.78, a significant decrease from CNY 416,111,137.75 in the same period last year, representing a decline of approximately 89.1%[21] - The total profit before tax was CNY 74,352,639.96, down from CNY 471,149,241.11 in the same quarter last year, reflecting a decline of about 84.3%[21] - The total comprehensive income for the period was CNY 38,732,653.47, a decrease from CNY 429,534,028.97 in the previous year, representing a decline of about 91%[21] Assets and Liabilities - Total assets decreased by 9.25% to ¥7,749,738,238.17 compared to the end of the previous year[3] - Shareholders' equity attributable to the parent company decreased by 11.68% to ¥3,065,164,116.02[3] - Total liabilities decreased to ¥4,640,991,667.99 from ¥5,007,327,600.82, a reduction of approximately 7.31%[19] - Non-current assets totaled ¥2,184,311,145.62, slightly up from ¥2,172,731,507.62, showing a growth of about 0.53%[19] - Short-term borrowings decreased to ¥2,162,000,342.62 from ¥2,598,920,737.98, a decline of about 16.86%[19] - The company reported a decrease in accounts payable to ¥70,860,420.88 from ¥79,531,391.70, representing a reduction of approximately 10.93%[19] Cash Flow - Cash flow from operating activities for the year-to-date increased by 61.02% to ¥1,603,186,609.10[2] - Net cash flow from operating activities increased by 61.02% year-on-year, driven by a decrease in raw material procurement[8] - The cash flow from operating activities netted CNY 1,603,186,609.10, an increase from CNY 995,638,605.50 in the prior year, reflecting a growth of approximately 60.9%[22] - Investment activities generated a net cash flow of CNY 215,204,783.54, a turnaround from a negative cash flow of CNY -18,319,902.96 in the same period last year[23] - Cash flow from financing activities decreased by 297.66% year-on-year, as cash outflows for loan repayments and share buybacks exceeded inflows[10] Expenses and Financial Performance - Financial expenses increased by 90.60% year-on-year, with interest expenses rising by 37.55% due to an increase in loan scale[8] - The company incurred financial expenses of CNY 53,928,133.24, up from CNY 28,293,622.86 in the previous year, marking an increase of about 90.5%[21] - Research and development expenses for the period were ¥72,436,744.27, up from ¥61,110,369.60, indicating an increase of approximately 18.93%[20] - Operating profit, total profit, net profit, and net profit attributable to shareholders decreased by 87.04%, 84.22%, 89.13%, and 84.28% respectively, mainly due to increased operating costs and reduced investment income[8] Inventory and Receivables - Inventory decreased by 46.22% compared to the beginning of the year, primarily due to lower sales and the timing of raw material procurement[7] - Other receivables increased by 142.88% year-to-date, mainly due to financial assistance provided to joint ventures[7] - The company's inventory at the end of the reporting period remained at a reasonable and healthy level[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,170, with the top ten shareholders holding significant stakes[11] - The company repurchased a total of 49.6739 million shares, accounting for 9.32% of the total share capital, with a total transaction amount of RMB 492 million[16] Business Performance - The company achieved a revenue of RMB 5.225 billion in the first three quarters, representing a year-on-year growth of 1.08%[15] - The revenue from plant extract business reached RMB 2.328 billion, with a year-on-year increase of 11.11%[15] - The sales volume of chili red pigment was 6,573 tons, a decrease of 14.35% year-on-year[15] - The sales volume of lutein reached 330 million grams, marking a new high for the period[15] - The revenue from stevia continued to grow rapidly, achieving RMB 182 million in the first three quarters, a new high for the period[15] - The gross margin for plant extract business was 15.95%, down 6.12% year-on-year[15] - The company plans to develop over 200,000 acres of marigold planting bases domestically and internationally in 2024[15]

晨光生物科技集团股份有限公司 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（以下简称"公司"）董事会于 2024 年 10 月 19 日以专人送达、邮件方式向全体董事发出第五届董事会第十三次会议通知， 会议于 2024 年 10 月 24 日在公司会议室以现场与通讯相结合的方式召开。本次 会议由董事长卢庆国先生主持，应出席会议董事六人，实际出席会议董事六人（董 事长卢庆国，独立董事戴小枫、厉梁秋、牛翃以通讯表决方式参加），公司监事、 高级管理人员列席了本次会议，本次会议召开符合《公司法》《公司章程》等有 关规定。经与会董事研究、讨论，审议通过以下议案： 一、 审议通过了《关于<2024 年第三季度报告>的议案》 证券代码：300138 证券简称：晨光生物 公告编号：2024—138 二、 审议通过了《关于计提资产减值准备的议案》 表决结果：同意六票；反对零票；弃权零票。 议案具体内容、监事会发表的意见，详见巨潮资讯网同期披露的相关文件。 特此公告 晨光生物科技集团股份有限公司 董事会 2024 ...